Background and Purpose-There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions-Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.
I
ntravenous thrombolysis (IVT) with alteplase within 4.5 hours from stroke onset is an evidence-based treatment for acute ischemic stroke. 1 IVT is still underused due to large number of contraindications in the summary of product characteristics. 2 One safety-related contraindication is prior treatment with low molecular weight heparins (LMWHs) within 24 hours of stroke onset. 3 The 2015 American Heart Association guidelines on the early management of patients with acute ischemic stroke contraindicated IVT in patients treated with LMWHs, irrespective of dosage. 4 This was updated in the latest American Heart Association guidelines in 2018, in which lower, prophylactic doses of LMWHs were exempted from this general rule. 5, 6 The evidence base for this updated recommendation is, however, unclear. LMWHs at low doses are commonly prescribed for the prevention of deep venous thrombosis. They do not typically prolong the activated partial thromboplastin time, and there are no established guidelines for the evaluation of LMWH activity at thromboprophylactic doses with anti-factor Xa assays. 7 Data are scarce on IVT treatment in ischemic stroke patients who have received LMWHs, with few such patients included in studies of off-label use of IVT in stroke. [8] [9] [10] The largest reported number of stroke IVT in patients on LMWHs, n=21, was reported from Spain in 2012. Of these, 16 were on low thromboprophylactic doses, while 5 were taking higher therapeutic doses. 11 This study reported an elevated risk of symptomatic intracerebral hemorrhage
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May 2019 (SICH) and death in LMWH patients. However, results were reported for all patients receiving LMWH without grouping by prophylactic and therapeutic dose, which makes the findings difficult to interpret. We aimed to investigate the safety of IVT treatment in patients on prophylactic doses of LMWHs at stroke onset.
Methods
All IVT-treated patients registered in the Safe Implementation of Treatments in Stroke (SITS)-International Stroke Thrombolysis Registry (ISTR) between January 2003 and December 2017 were considered for inclusion in the present study. Patients treated with oral anticoagulants or therapeutic doses of heparinoids at stroke onset, as well as patients undergoing endovascular procedures in addition to IVT, were excluded from the analysis. The SITS-ISTR is a multinational, prospective, observational monitoring register documenting data for centers using IVT for acute ischemic stroke. The aims of the register, collection of data, and structure of the database have been described previously. [12] [13] [14] [15] [16] Baseline and demographic characteristics, stroke severity per the National Institutes of Health Stroke Scale, risk-factors, time logistics, medication history, imaging data, and 3-month outcome data were registered. In the SITS-ISTR, there are data if the patient is on LMWH at low doses for prophylaxis of deep venous thrombosis at the time of stroke onset.
Ethical Approval and Data Monitoring
The need for ethical approval or patient consent for participation in SITS-ISTR varied among participating countries, but approvals were obtained in countries that required this; other countries approved the register for conduct as an anonymized audit. The study was approved as part of the SITS-MOST-II study framework by the Regional Research Ethics Committee in Stockholm, Sweden. The SITS International Coordination Office performed regular online monitoring of the SITS-ISTR data online and checked individual patient data on a regular basis to identify errors or inconsistencies.
Outcome Measurements
The main outcome measure was SICH per the SITS-MOST definition: a local or remote type 2 parenchymal hematoma (PH) on imaging 22 to 36 hours after treatment, or earlier if the scan was performed because of clinical deterioration, combined with a neurological deterioration of ≥4 National Institutes of Health Stroke Scale points or leading to death within 24 hours. Secondary outcome measures included SICH per the ECASS II definition (any type of intracerebral hemorrhage on any post-treatment imaging after the start of IVT and increase of ≥4 National Institutes of Health Stroke Scale points or death within 7 days), SICH per the National Institute of Neurological Disorders and Stroke definition (any deterioration in National Institutes of Health Stroke Scale or death within 7 days, combined with any intracerebral hemorrhage [including petechial] on any post-treatment imaging), 24-hour PH (any type of PH on 24-hour computed tomography or magnetic resonance imaging irrespective of clinical symptoms), 7-day mortality, 3-month mortality, and 3-month functional dependency and death (defined as modified Rankin Scale score 3-6). All assessments of imaging studies and neurological status were done according to clinical routine at centers participating in the SITS-ISTR. SICH event adjudication was performed by the SITS International Coordination Office on the basis of available clinical and imaging data entered by the investigators in the registry.
Statistical Analysis
Descriptive statistics for baseline, demographic, and imaging data were performed, comparing patients receiving prophylactic LMWH with patients not receiving prophylactic LMWH before IVT. Proportions were calculated for categorical variables, dividing the number of events by the total number excluding missing or unknown.
Missing data were not imputed. Medians were calculated for continuous and ordinal variables. Statistical significance for differences between proportions was evaluated by the χ 2 method, while for medians the Mann-Whitney U test was used. Univariate and adjusted odds ratios were calculated. Multivariate adjustment was conducted using logistic regression analysis. For each main outcome, starting with a model including all available baseline variables, a backward stepwise procedure was performed using P>0.05 of the likelihood ratio test for exclusion. The grouping parameter on LMWH status was kept in the respective models irrespective of significance as the association of LMWH with the respective outcome was the main purpose of the analyses.
Additionally, we also performed treatment effects analysis for all outcome parameters using propensity score matching, to reduce confounding because of baseline differences between the 2 treatment groups. Propensity scores for receiving LMWH were calculated for each patient based on the recorded baseline parameters. Subsequently, we matched patients with similar propensity scores in the LMWH and non-LMWH groups on a 1:1 basis. All analyses were performed in Stata version 14.2.
Data Availability
Data related to the current study are derived from the SITS-ISTR. Access to the anonymized SITS-ISTR data will be available from the corresponding author (Dr Cooray) on reasonable request and approval by the SITS Scientific Committee.
Results
Between January 2003 and December 2017, a total of 109 291 acute ischemic stroke patients treated with IVT and not on treatment with oral anticoagulant or therapeutic heparin treatment were registered, with complete data on prophylactic LMWH treatment status before IVT (see Figure I in the online-only Data Supplement for a patient selection flow diagram). Of these, 1411 patients (1.3%) were on prophylactic LMWHs at stroke onset. Patients on prophylactic LMWHs were older, had more severe strokes, higher prevalence of atrial fibrillation and more frequent preexisting disability and history of previous stroke. Other comorbidities, such as diabetes mellitus, hypertension, and congestive heart failure, were also more common in the prophylactic LMWH group. Table 1 shows the baseline characteristics of the 2 groups.
The difference in the unadjusted rate of SICH per SICH-MOST was not significantly different between the treatment groups. Unadjusted rates of SICH per the 2 other definitions, as well as radiological findings of PH on follow-up imaging, were significantly higher in LMHW patients (Table 2) . After adjustment for age, stroke severity, sex, systolic blood pressure, prestroke disabilities, onset-to-treatment time, dose of alteplase, smoking status, previous stroke, medications, and comorbidities, prophylactic LMWH treatment was not associated with either SICH per any of the 3 definitions, with PH, or 7-day mortality ( 
Propensity Score Analysis
A treatment effects model using propensity score analysis matched the LMWH and non-LMWH patients on all available baseline parameters, with no remaining significant differences in baseline parameters between groups following the matching procedure (see Table I in the online-only Data Supplement for comparison of baseline characteristics between LMWH and non-LMWH groups for 3 months outcome analysis after matching). This resulted in much smaller, and statistically nonsignificant differences in all outcomes except death within 3 months, which remained higher in LMWH patients ( Table 4 ). As seen in Table 4 , the prematching and postmatching LMWH groups (ie, the LMWH-treated group before the matching procedure and the remaining LMWH-treated group after the matching procedure) were similar with respect to the outcomes, with the exception of 7-day mortality, in which the matching procedure generated a group with a clearly lower rate of 7-day mortality (21.2% versus 10.1%). Table II 
Discussion
We have conducted a large observational study of 1411 patients with acute ischemic stroke, treated with IVT while receiving treatment with thromboprophylactic doses of LMWHs. We did not find any independent effect of lowdose LMWH on the safety of stroke thrombolysis, specifically on the occurrence of SICH, PH, and early death. These results strengthen the evidence base for the recently updated recommendations from the American Heart Association, exempting prophylactic doses of LMWH from the general contraindication to IVT treatment in acute ischemic stroke on LMWHs.
5,6
Patients on low-dose LMWH treatment had more severe strokes, had a much higher burden of comorbidities, and were somewhat older. This translated into clearly worse functional outcomes and more patients dead at 3-month follow-up. After multivariate analysis adjusting for the extensive baseline differences between the groups, higher adjusted odds for death, as well as death or dependency at 3 months remained in the low-dose LMWH group. Because we did not find an independent association of low-dose LMWH with any early safety outcomes, we think that the remaining differences in 3 months outcomes are likely because of unmeasured (ie, unknown) differences between the groups that we were not able to control for in the multivariate logistic regression analysis. This interpretation is supported by the propensity score analysis, which matched patients in the 2 treatment groups on the available baseline data and showed no significant differences between the 2 groups for any outcomes except death within 3 months (Table 3 ). The absolute difference in 3-month mortality, although still statistically significant, was substantially reduced after matching. In light of the reassuring results about shorter-term safety outcomes, we think that the remaining differences in 3 months outcomes could be explained by residual confounding which we were unable to control for. It is highly unlikely that any direct adverse effect of LMWH administered near the time of stroke onset would translate into long-term higher mortality while at the same time not affecting the shortterm outcomes, including 7-day mortality.
So far, data on this issue has only been available from low numbers of patients included in general studies on off-label IVT in stroke. 8, 9 Hitherto, the largest number of IVT in patients with stroke on LMWHs was reported in a study from 5 Spanish hospitals, where 21 patients taking subcutaneous LMWH had been treated. Of these, 16 were on low thromboprophylactic doses and 5 had higher therapeutic doses. 11 The Spanish study found that LMWH was associated with 8-fold higher adjusted odds for SICH, 5-fold higher adjusted odds CT indicates computed tomography; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NINDS, National Institute of Neurological Disorders and Stroke; OR, odds ratio; SICH, symptomatic intracerebral hemorrhage; SITS, Safe Implementation of Treatments in Stroke; and TIA, transient ischemic attack.
*The multivariate analysis corrected for (1) common in all analyses-NIHSS, age, onset-to-treatment, and smoker; (2) SICH per SITS-MOST definition-systolic blood pressure and sex; (3) SICH per ECASS definition-systolic blood pressure, sex, previous stroke, congestive heart failure, and weight; (4) SICH per NINDS definition-systolic blood pressure, statins, aspirin, weight, and sex; (5) 24-h parenchymal hemorrhage-systolic blood pressure; (6) 7-d mortality-systolic blood pressure, sex, prestroke mRS, TIA, statins, early infarct signs on CT, weight, dose of alteplase, congestive heart failure, previous stroke, sex, and aspirin; (7) 3-mo mortality-sex, prestroke mRS, aspirin, hyperlipidemia, early infarct signs on CT, weight, and alteplase; and (8) 3-mo functional dependency or death-prestroke mRS, hyperlipidemia, glucose, early infarct signs on CT, aspirin, weight, and alteplase.
for death, and around 70% lower adjusted odds for functional independence at 3 months, compared with patients without any anticoagulants. However, this analysis pooled patients with high and low LMWH dose regiments, precluding conclusions on the safety of IVT specifically in the setting of lowdose prophylactic LMWH. Differences in absolute percentages (%) before and after propensity score matching are given with associated P values and compare LMWH patients against non-LMWH patients. Negative values indicate a lower percentage of the respective outcome in the LMWH vs non-LMWH group after matching. Number in parentheses gives the number of treated patients matched against controls on a 1:1 basis after the matching procedure. LMWH indicates low molecular weight heparin; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SICH, symptomatic intracerebral hemorrhage; SITS, Safe Implementation of Treatments in Stroke; and TIA, transient ischemic attack.
*The following parameters were used for matching the cohorts: glucose, TIA, previous stroke, early infarct signs, prestroke mRS, congestive heart failure, atrial fibrillation, smoker, hyperlipidemia, diabetes mellitus, hypertension, statins, aspirin, clopidogrel, sex, onset-to-treatment, weight, age, systolic blood pressure, NIHSS, and dose of alteplase. Our study has certain limitations that need mention. It is based on a retrospective analysis of an ongoing database, with all the limitations pertaining to this type of study design. Differences in demographic and patient characteristics were adjusted for through multivariate analysis and treatment effects modeling, and these statistical methods may not account for all imbalances, in particular in unrecorded variables. Important to note, the matching procedure resulted in similar prematching and postmatching LMWH groups with regard to the respective outcomes as well as baseline characteristics, which supports the extrapolation of the propensity score analysis results to real-time clinical practice. This was true for all outcomes except 7-day mortality in which the postmatching LMWH group showed a clearly lower rate of 7-day mortality compared with the prematched group (21.2% versus 10.1%). We, however, do not think that this changes the main conclusion of the article overall, considering that the logistic regression based adjustment of 7-day mortality eliminated the preadjustment differences between the cohorts. An important limitation is that the SITS-ISTR does not collect data for the exact dose of LMWH, preventing the investigation of dose-dependence of any adverse outcomes. Another limitation is the lack of information on the extent of early infarct signs on pre-IVT computed tomography scans. Although a dichotomized variable on early infarct signs did not show any association with hemorrhagic complications, one could expect a positive association in the case of extensive infarctions. This association is of clinical interest to stroke physicians but is unfortunately untestable in the current data set and limits the external validity of the results. Finally, the lack of information on pretreatment renal function hinders the possibility of assessing the association between LMWH clearance and hemorrhagic complications. Nevertheless, despite the listed limitations, based on data from a large number of patients treated at 974 centers in 59 countries, we think our results to be representative of realworld practice.
Conclusions
In this study, IVT treatment in patients with acute ischemic stroke on treatment with low doses of LMWH at stroke onset is not associated with an increased risk of SICH or early death. Our findings indicate that IVT in patients with acute ischemic stroke on LMWH at stroke onset most likely is safe and provides support for the recently updated American Heart Association guidelines. Further prospective studies are needed to confirm our findings.
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